# A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT05241093** · PHASE2 · RECRUITING · sponsor: **Tarapeutics Science Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** HYML-122; cytarabine

## Key facts

- **NCT ID:** NCT05241093
- **Lead sponsor:** Tarapeutics Science Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-29
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241093, "A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05241093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*